secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0000950170-24-126317
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi nominates MGX-001 DC for hemophilia A; reports $274.6M cash; Q3 expenses down
--------------------------------------------------------------------------------

- Nominated MGX-001 as first development candidate for hemophilia A; IND-enabling activities initiated, IND filing on track for 2026.
- Cash, cash equivalents and marketable securities $274.6M at Sept 30, 2024; cash runway expected into 2027.
- R&D expenses $26.3M in Q3 2024 (vs $26.8M Q3 2023); G&A $7.6M (vs $7.9M).
- Ionis collaboration: all four wave 1 programs in lead optimization; one to two DC nominations expected in 2025.
- Novel ABE platform targets >95% of genome base pairs; SMART platform enables single-AAV delivery for neuromuscular.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000095017024126317/0000950170-24-126317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000095017024126317/mgx-20241113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-126317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer